Tafasitamab

Tafasitamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hodgkin Lymphoma、B-Cell Lymphoma、Relapsed B-cell NHL。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

22 项

全球在招研究

1 项

已进入 III/IV 期

12 个

开展国家和地区

有

中国境内设点

药品与企业信息

研发企业

M.D. Anderson Cancer Center
Incyte Biosciences Italy S.r.l
Incyte Corporation
Academic and Community Cancer Research United
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
University of Washington
IRCCS Azienda Ospedaliero-Universitaria di Bologna
University Hospital Tuebingen

汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。

生产企业

公开药品批准资料或正式说明书暂未提供明确的生产企业信息。

研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。

主要开展国家和地区

意大利、美国、澳大利亚、法国、荷兰、西班牙、英国、德国、中国、Hungary、South Korea、Turkey (Türkiye)

正在招募患者的 Tafasitamab 研究

中国患者怎么争取用上这款药

这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。

同类方向的其他在研新药

Carboplatin Pembrolizumab Cyclophosphamide Rituximab Venetoclax Azacitidine Dexamethasone Doxorubicin

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。

Tafasitamab

药品与企业信息

研发企业

生产企业

主要开展国家和地区

正在招募患者的 Tafasitamab 研究

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

中国患者怎么争取用上这款药

同类方向的其他在研新药